Advertisement

After successful results from its multi-site clinical studies, Avedro Inc. has filed a new drug application to the U.S. Food and Drug Administration for the treatment of keratoconus, a degenerative eye disease found to be the leading cause of corneal transplants in the U.S., and corneal ectasia. If approved, the maker of products for Lasik surgery and other non-invasive ophthalmic procedures will have seven years of exclusive marketing rights in the U.S. for its riboflavin ophthalmic solution, VibeX.

SOURCE

Advertisement
Advertisement